le Roux 2024 - Survodutide Phase 2 Trial for Obesity

The Lancet Diabetes & Endocrinology·February 1, 2024

Carel W. le Roux

Summary

Survodutide produced dose-dependent weight loss in adults with obesity or overweight and supported later phase 3 obesity trials.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled dose-finding trial

Indication

Obesity or overweight

Intervention

Survodutide / BI 456906 vs placebo

Species

Human

Risk of Bias Assessment

Sponsor-funded dose-finding trial